The company currently has around $3 billion in cash and has already completed two notable acquisitions in recent years—Concert Pharmaceuticals, which brought in Leqselvi, and Checkpoint Therapeutics, which added Unloxcyt to its pipeline.
Sun Pharma also plans to spend $100 million in FY26 on the US launch of these two new specialty products. “This spend will cover all the launch-related expenses in the current fiscal,” Muralidharan noted.
Additionally, the company is increasing R&D investment to 6-8% of sales, with the additional expenditure going toward clinical trials of its pipeline products.
While the company did not provide specific margin guidance for FY26, Muralidharan said “our key core drivers, like the global specialty business, India, emerging markets, and other segments, are well-positioned to grow,” adding that the company will continue to focus on cost and operational efficiencies to improve profitability. Revenue growth for FY26 is expected in the mid to high single digits, he added.
The comments come after the company posted mixed results for Q4FY25. While revenue grew 8.1% year-on-year to ₹12,958.8 crore and EBITDA surged 22.4%, net profit fell 19% to ₹2,153.9 crore, missing Street expectations.
Watch accompanying video for entire conversation.
